Skip to main content

Neogen Corporation (NEOG) Stock Analysis

Range Bound setup

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Medical Devices

Sell if holding. Engine safety override at $9.34: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Elevated put/call ratio: 3.33; Below-average business quality; Negative price momentum.

Neogen Corporation develops and markets food safety diagnostics (test kits, culture media, software) and animal safety products (veterinary instruments, pharmaceuticals, genomics) globally. Following the 2022 merger with 3M's Food Safety Division, ~50.2% of fiscal 2025 revenue... Read more

$9.34+9.1% A.UpsideScore 4.7/10#38 of 40 Medical Devices
Stop $8.69Target $10.20(analyst − 15%)A.R:R 1.1:1
Analyst target$12.00+28.5%3 analysts
$10.20our TP
$9.34price
$12.00mean
$13

Sell if holding. Engine safety override at $9.34: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Elevated put/call ratio: 3.33; Below-average business quality; Negative price momentum. Chart setup: RSI 49 mid-range, Bollinger mid-band. Score 4.7/10, moderate confidence.

Passes 5/7 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 90d clear, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Geographic: international revenue (outside U.S.) (50.2%)
Concentration risk — Supplier: sole or single source supplier for food safety product lines
Quality below floor (3.2 < 4.0)

Key Metrics

P/E (TTM)
P/E (Fwd)30.4
Mkt Cap$2.0B
EV/EBITDA32.0
Profit Mgn-69.9%
ROE-25.6%
Rev Growth-4.4%
Beta1.97
DividendNone
Rating analysts11

Quality Signals

Piotroski F6/9

Options Flow

P/C3.33bearish
IV51%elevated
Max Pain$3-73.2% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHGeographicinternational revenue (outside U.S.)50%
    10-K Item 1A: 'In fiscal year 2025, sales to customers outside of the U.S. accounted for 50.2% of our total revenue'
  • HIGHSuppliersole or single source supplier for food safety product lines
    10-K Item 1A: 'Certain of our food safety product lines depend on a sole or single source supplier or vendor.'

Material Events(8-K, last 90d)

  • 2026-03-30Item 5.02MEDIUM
    Amy Rocklin, Chief Legal and Administrative Officer, will leave the Company effective March 31, 2026. No reason cited, no successor named.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
0.0
Quality Rank
0.9
Value Rank
5.7

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume
0.0
Obv
1.0
Macd
3.7
Ma Position
4.0
Rsi
5.5
Volume distribution (falling OBV)Above 200-day MA

Unprofitable operations — net margin -69.9%. Quality floor flags this regardless of sector context.static

Roe
0.0
Roa
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
3.4
Gross Margin
5.0
Moat
5.0
Piotroski F
6.7
Current Ratio
9.1
FCF-positive but moderate margins (FCF margin 2%, FCF yield 1.0%)No competitive moat
GatesMomentum 2.8<4.5A.R:R 1.1 < 1.5@spotInsider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 90d clearSEMI CYCLE PEAK CLEARRange BoundSuitability: Aggressive
RSI
49 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $8.92Resistance $10.83

Price Targets

$9
$10
A.Upside+9.2%
A.R:R1.1:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (3.2 < 4.0)
! Momentum score 2.8/10 — below 4.5 minimum
! Reward/Risk 1.1:1 at current price — below 1.5:1 minimum

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-07-29 (90d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is NEOG stock a buy right now?

Sell if holding. Engine safety override at $9.34: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Elevated put/call ratio: 3.33; Below-average business quality; Negative price momentum. Chart setup: RSI 49 mid-range, Bollinger mid-band. Prior stop was $8.69. Score 4.7/10, moderate confidence.

What is the NEOG stock price target?

Take-profit target: $10.20 (+9.1% upside). Prior stop was $8.69. Stop-loss: $8.69.

What are the risks of investing in NEOG?

Concentration risk — Geographic: international revenue (outside U.S.) (50.2%); Concentration risk — Supplier: sole or single source supplier for food safety product lines; Quality below floor (3.2 < 4.0).

Is NEOG overvalued or undervalued?

Neogen Corporation trades at a P/E of N/A (forward 30.4). TrendMatrix value score: 5.7/10. Verdict: Sell.

What do analysts say about NEOG?

11 analysts cover NEOG with a consensus score of 3.9/5. Average price target: $12.

What does Neogen Corporation do?Neogen Corporation develops and markets food safety diagnostics (test kits, culture media, software) and animal safety...

Neogen Corporation develops and markets food safety diagnostics (test kits, culture media, software) and animal safety products (veterinary instruments, pharmaceuticals, genomics) globally. Following the 2022 merger with 3M's Food Safety Division, ~50.2% of fiscal 2025 revenue came from outside the U.S. The company is integrating the 3M FSD business and recorded impairment charges in fiscal 2025.

Related stocks: GMED (Globus Medical, Inc.) · TMDX (TransMedics Group, Inc.) · INSP (Inspire Medical Systems, Inc.) · HAE (Haemonetics Corporation) · AXGN (AxoGen, Inc.)